{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:16:19Z","timestamp":1780373779848,"version":"3.54.1"},"reference-count":81,"publisher":"BMJ","issue":"3","funder":[{"DOI":"10.13039\/501100012317","name":"UCLH Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2024,7,3]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>Human immunoglobulin, delivered either intravenously (IVIg) or subcutaneously, is used to treat a range of immune-mediated neurological disorders. It has a role in acute or subacute inflammatory disease control and as a maintenance therapy in chronic disease management. This review considers mechanisms of IVIg action and the evidence for IVIg in neurological conditions. We use Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) as frameworks to demonstrate an approach to IVIg use in acute and chronic dysimmune neurological conditions across two different healthcare systems: the UK and Australia. We highlight the benefits and limitations of IVIg and focus on practical considerations such as informed consent, managing risks and adverse effects, optimal dosing and monitoring response. We use these basic clinical practice principles to discuss the judicious use of an expensive and scarce blood product with international relevance.<\/jats:p>","DOI":"10.1136\/pn-2022-003655","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T13:21:05Z","timestamp":1722691265000},"page":"228-240","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Immunoglobulin use in neurology: a practical approach"],"prefix":"10.1136","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-3426","authenticated-orcid":false,"given":"Mahima","family":"Kapoor","sequence":"first","affiliation":[{"name":"Neuroscience \/ FMNHS \/ School of Translational Medicine, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3493-5202","authenticated-orcid":false,"given":"Anthony","family":"Khoo","sequence":"additional","affiliation":[{"name":"Flinders University College of Medicine and Public Health, Adelaide, South Australia, Australia"},{"name":"Department of Neurology, Flinders Medical Centre, Bedford Park, South Australia, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-6027","authenticated-orcid":false,"given":"Michael P T","family":"Lunn","sequence":"additional","affiliation":[{"name":"Centre for Neuromuscular Diseases, National Hospital for Neurology and Neurosurgery, London, UK"},{"name":"UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Reddel","sequence":"additional","affiliation":[{"name":"ANZAC Research Institute, Central Clinical School, University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisling S","family":"Carr","sequence":"additional","affiliation":[{"name":"UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"key":"2025090411014483000_25.3.228.1","unstructured":"Foster M . The 11th national immunoglobulin database report 2020 - 2021. NHS, England, 2022."},{"key":"2025090411014483000_25.3.228.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1085-9489.2006.00061.x"},{"key":"2025090411014483000_25.3.228.3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/ACI.0000000000000696","article-title":"Global immunoglobulin supply: steaming towards the iceberg?","volume":"20","author":"Prevot","year":"2020","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2025090411014483000_25.3.228.4","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31824e8f84"},{"key":"2025090411014483000_25.3.228.5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3390\/biom6010015","article-title":"The production processes and biological effects of intravenous immunoglobulin","volume":"6","author":"Barahona Afonso","year":"2016","journal-title":"Biomolecules"},{"key":"2025090411014483000_25.3.228.6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/cei.1996.104.s1.35","article-title":"The viral safety of intravenous immune globulin","volume":"104","author":"Yap","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"2025090411014483000_25.3.228.7","doi-asserted-by":"publisher","DOI":"10.1136\/pn-2021-002991"},{"key":"2025090411014483000_25.3.228.8","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002567"},{"key":"2025090411014483000_25.3.228.9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117520"},{"key":"2025090411014483000_25.3.228.10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/acn3.326","article-title":"Dose-dependent inhibition of demyelination and microglia activation by IVIG","volume":"3","author":"Winter","year":"2016","journal-title":"Ann Clin Transl Neurol"},{"key":"2025090411014483000_25.3.228.11","doi-asserted-by":"crossref","first-page":"1756286421997381","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"2025090411014483000_25.3.228.12","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14737175.2022.2169134","article-title":"Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"2025090411014483000_25.3.228.13","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","article-title":"Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the lambert-eaton myasthenic syndrome","volume":"47","author":"Bain","year":"1996","journal-title":"Neurology (ECronicon)"},{"key":"2025090411014483000_25.3.228.14","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70282-5"},{"key":"2025090411014483000_25.3.228.15","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/jca.22055","article-title":"Neonatal Fc receptor blockade as emerging therapy in diseases with plasma exchange indications","volume":"38","author":"Yunce","year":"2023","journal-title":"J Clin Apher"},{"key":"2025090411014483000_25.3.228.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2007.11.020"},{"key":"2025090411014483000_25.3.228.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00077-7"},{"key":"2025090411014483000_25.3.228.18","doi-asserted-by":"publisher","DOI":"10.1038\/nri2206"},{"key":"2025090411014483000_25.3.228.19","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.0000000000006625","article-title":"Ultrastructural mechanisms of macrophage-induced demyelination in CIDP","volume":"91","author":"Koike","year":"2018","journal-title":"Neurology (ECronicon)"},{"key":"2025090411014483000_25.3.228.20","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2021-003073"},{"key":"2025090411014483000_25.3.228.21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.7861\/clinmedicine.15-2-125","article-title":"False interpretation of diagnostic serology tests for patients treated with pooled human immunoglobulin G infusions: a trap for the unwary","volume":"15","author":"Bright","year":"2015","journal-title":"Clin Med (Lond)"},{"key":"2025090411014483000_25.3.228.22","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaip.2013.05.014","article-title":"Administration of intravenous immunoglobulin to a patient with hypogammaglobulinemia and anti-IgA antibodies","volume":"1","author":"Lieberman","year":"2013","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025090411014483000_25.3.228.23","doi-asserted-by":"crossref","first-page":"116527","DOI":"10.1016\/j.jns.2019.116527","article-title":"Routine blood monitoring in maintenance immunoglobulin treatment of inflammatory neuropathy: is it clinically relevant?","volume":"408","author":"Keh","year":"2020","journal-title":"J Neurol Sci"},{"key":"2025090411014483000_25.3.228.24","doi-asserted-by":"publisher","DOI":"10.1385\/CRIAI:29:3:173"},{"key":"2025090411014483000_25.3.228.25","doi-asserted-by":"publisher","DOI":"10.1381\/0960892054621350"},{"key":"2025090411014483000_25.3.228.26","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.11.1689"},{"key":"2025090411014483000_25.3.228.27","article-title":"Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome","volume":"6","author":"Hughes","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090411014483000_25.3.228.28","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325815"},{"key":"2025090411014483000_25.3.228.29","first-page":"e518","article-title":"Predicting outcome in Guillain-Barr\u00e9 syndrome: international validation of the modified erasmus GBS outcome score","volume":"98","author":"Doets","year":"2022","journal-title":"Neurology (ECronicon)"},{"key":"2025090411014483000_25.3.228.30","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16230","article-title":"Response to letter on european academy of neurology\/peripheral nerve society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"31","author":"van Doorn","year":"2024","journal-title":"Eur J Neurol"},{"key":"2025090411014483000_25.3.228.31","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30494-4"},{"key":"2025090411014483000_25.3.228.32","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2019-002336"},{"key":"2025090411014483000_25.3.228.33","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/brain\/awaa433","article-title":"Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barr\u00e9 syndrome","volume":"144","author":"Keddie","year":"2021","journal-title":"Brain (Bacau)"},{"key":"2025090411014483000_25.3.228.34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/jns.12481","article-title":"Predicting long-term trends in inflammatory neuropathy outcome measures using latent class modelling","volume":"27","author":"Keh","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"2025090411014483000_25.3.228.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)09095-2"},{"key":"2025090411014483000_25.3.228.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2010.00290.x"},{"key":"2025090411014483000_25.3.228.37","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-013-0329-z","article-title":"Update on treatment of inclusion body myositis","volume":"15","author":"Breithaupt","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2025090411014483000_25.3.228.38","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","article-title":"Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies","volume":"33","author":"Dalakas","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"2025090411014483000_25.3.228.39","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/14737175.2017.1340832","article-title":"Comparing treatment options for chronic inflammatory neuropathies and choosing the right treatment plan","volume":"17","author":"Nobile-Orazio","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"2025090411014483000_25.3.228.40","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/ene.12767","article-title":"Disease status in chronic inflammatory demyelinating polyneuropathy: inter-centre comparative analysis and correlates","volume":"22","author":"Rajabally","year":"2015","journal-title":"Eur J Neurol"},{"key":"2025090411014483000_25.3.228.41","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ncl.2013.01.001","article-title":"Multifocal motor neuropathy, multifocal acquired demyelinating sensory and motor neuropathy, and other chronic acquired demyelinating polyneuropathy variants","volume":"31","author":"Dimachkie","year":"2013","journal-title":"Neurol Clin"},{"key":"2025090411014483000_25.3.228.42","article-title":"Immunoglobulin for multifocal motor neuropathy","volume":"1","author":"Keddie","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090411014483000_25.3.228.43","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12190"},{"key":"2025090411014483000_25.3.228.44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00415-008-3003-z","article-title":"The role of IVIg in autoimmune neuropathies: the latest evidence","volume":"255 Suppl 3","author":"Hughes","year":"2008","journal-title":"J Neurol"},{"key":"2025090411014483000_25.3.228.45","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awab422","article-title":"Randomized trial of three ivig doses for treating chronic inflammatory demyelinating polyneuropathy","volume":"145","author":"Cornblath","year":"2022","journal-title":"Brain (Bacau)"},{"key":"2025090411014483000_25.3.228.46","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/jns.12158","article-title":"A proposed dosing algorithm for the individualized dosing of human immunoglobulin in chronic inflammatory neuropathies","volume":"21","author":"Lunn","year":"2016","journal-title":"J Peripher Nerv Syst"},{"key":"2025090411014483000_25.3.228.47","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30378-2"},{"key":"2025090411014483000_25.3.228.48","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.12968\/bjon.2012.21.Sup5.S21","article-title":"A comparison between intravenous and subcutmaneous immunogobulin","volume":"21","author":"Braine","year":"2012","journal-title":"Br J Nurs"},{"key":"2025090411014483000_25.3.228.49","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00415-020-10318-3","article-title":"Subcutaneous immunoglobulin dose titration to clinical response in inflammatory neuropathy","volume":"268","author":"Kapoor","year":"2021","journal-title":"J Neurol"},{"key":"2025090411014483000_25.3.228.50","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12402"},{"key":"2025090411014483000_25.3.228.51","unstructured":"England N . Commissioning criteria policy for the use of therapeutic immunoglobulin in england. Available: https:\/\/www.england.nhs.uk\/publication\/commissioning-criteria-policy-for-the-use-of-therapeutic-immunoglobulin-ig-in-england-2021\/2021 [Accessed 26 Apr 2023]."},{"key":"2025090411014483000_25.3.228.52","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2013.06.006"},{"key":"2025090411014483000_25.3.228.53","doi-asserted-by":"publisher","DOI":"10.1002\/mus.880141111"},{"key":"2025090411014483000_25.3.228.54","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000001044"},{"key":"2025090411014483000_25.3.228.55","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology (ECronicon)"},{"key":"2025090411014483000_25.3.228.56","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/jns.12516","article-title":"Rasch-built overall disability scale for POEMS syndrome (POEMS-RODS)","volume":"27","author":"Keh","year":"2022","journal-title":"J Peripher Nerv Syst"},{"key":"2025090411014483000_25.3.228.57","first-page":"e1876","article-title":"Quantifying treatment-related fluctuations in CIDP: results of the GRIPPER study","volume":"96","author":"Allen","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025090411014483000_25.3.228.58","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1468-1331.2012.03851.x","article-title":"Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study","volume":"20","author":"Vanhoutte","year":"2013","journal-title":"Eur J Neurol"},{"key":"2025090411014483000_25.3.228.59","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4598(200009)23:9<1393::AID-MUS10>3.0.CO;2-O"},{"key":"2025090411014483000_25.3.228.60","first-page":"917","article-title":"Comparison of the grip strength using the martin-vigorimeter and the JAMAR-dynamometer: establishment of normal values","volume":"31","author":"Neumann","year":"2017","journal-title":"In Vivo"},{"key":"2025090411014483000_25.3.228.61","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1111\/ene.15496","article-title":"Association of plasma neurofilament light chain with disease activity in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"29","author":"Kapoor","year":"2022","journal-title":"Eur J Neurol"},{"key":"2025090411014483000_25.3.228.62","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad234"},{"key":"2025090411014483000_25.3.228.63","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/mus.24554","article-title":"Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"51","author":"Rajabally","year":"2015","journal-title":"Muscle Nerve"},{"key":"2025090411014483000_25.3.228.64","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2010.00284.x"},{"key":"2025090411014483000_25.3.228.65","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/jns.12470","article-title":"An approach to assessing immunoglobulin dependence in chronic inflammatory demyelinating inflammatory polyneuropathy","volume":"26","author":"Kapoor","year":"2021","journal-title":"J Peripher Nerv Syst"},{"key":"2025090411014483000_25.3.228.66","first-page":"e635","article-title":"Thromboembolic risk with ivig: incidence and risk factors in patients with inflammatory neuropathy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology (ECronicon)"},{"key":"2025090411014483000_25.3.228.67","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/brain\/awac054","article-title":"Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"145","author":"Adrichem","year":"2022","journal-title":"Brain (Bacau)"},{"key":"2025090411014483000_25.3.228.68","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199309040-00003"},{"key":"2025090411014483000_25.3.228.69","first-page":"S3","article-title":"Abstracts of the british peripheral nerve society \/ societe francophone du nerf peripherique 2020 joint meeting february 7-8, 2020","volume":"25","author":"F","year":"2020","journal-title":"J Peripher Nerv Syst"},{"key":"2025090411014483000_25.3.228.70","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-328881"},{"key":"2025090411014483000_25.3.228.71","doi-asserted-by":"publisher","DOI":"10.1159\/000494291"},{"key":"2025090411014483000_25.3.228.72","doi-asserted-by":"crossref","unstructured":"Hughes RAC , Swan AV , van Doorn PA . Intravenous immunoglobulin for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev 2014.:CD002063. doi:10.1002\/14651858.CD002063.pub6","DOI":"10.1002\/14651858.CD002063.pub6"},{"key":"2025090411014483000_25.3.228.73","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959"},{"key":"2025090411014483000_25.3.228.74","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14737175.2022.2057223","article-title":"Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis","volume":"22","author":"Dalakas","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"2025090411014483000_25.3.228.75","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325302"},{"key":"2025090411014483000_25.3.228.76","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","article-title":"Dermatomyositis: an update on diagnosis and treatment","volume":"21","author":"Cobos","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2025090411014483000_25.3.228.77","doi-asserted-by":"publisher","DOI":"10.1002\/art.10053"},{"key":"2025090411014483000_25.3.228.78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa01167"},{"key":"2025090411014483000_25.3.228.79","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/epi.12042","article-title":"Rasmussen encephalitis: incidence and course under randomized therapy with tacrolimus or intravenous immunoglobulins","volume":"54","author":"Bien","year":"2013","journal-title":"Epilepsia"},{"key":"2025090411014483000_25.3.228.80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1009433"},{"key":"2025090411014483000_25.3.228.81","doi-asserted-by":"crossref","first-page":"109782","DOI":"10.1016\/j.clim.2023.109782","article-title":"Intravenous immunoglobulin in kidney transplantation: mechanisms of action, clinical applications, adverse effects, and hyperimmune globulin","volume":"256","author":"Hou","year":"2023","journal-title":"Clin Immunol"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/pn-2022-003655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:09:35Z","timestamp":1757009375000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/pn-2022-003655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,5,15]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/pn-2022-003655"],"URL":"https:\/\/doi.org\/10.1136\/pn-2022-003655","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]}}}